Novavax (NVAX) director receives new RSUs and options and exercises prior RSU award
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Novavax director Margaret G. McGlynn reported equity compensation and an option exercise. On June 18, 2026, she received 14,180 Restricted Stock Units (RSUs) and 21,270 stock options, each RSU and option tied to one share of common stock. The options have a $9.13 per-share exercise price and will fully vest on the first anniversary of the grant date, subject to her continued board service.
On June 20, 2026, previously granted RSUs covering 18,880 shares vested and were exercised into the same number of Novavax common shares, leaving no remaining RSUs from that 2025 grant. After these transactions, she directly holds 44,468 shares of Novavax common stock. All reported activity reflects equity awards and vesting rather than any open-market buying or selling.
Positive
- None.
Negative
- None.
Insider Trade Summary
18,880 shares exercised/converted
Mixed
4 txns
Insider
MCGLYNN MARGARET G
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 18,880 | $0.00 | -- |
| Exercise | Common Stock | 18,880 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 21,270 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 14,180 | $0.00 | -- |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct, null);
Common Stock — 44,468 shares (Direct, null);
Stock Option (Right to Buy) — 21,270 shares (Direct, null)
Footnotes (1)
- Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Key Figures
RSUs exercised into common stock: 18,880 shares
New RSU grant: 14,180 units
New stock option grant: 21,270 options
+2 more
5 metrics
RSUs exercised into common stock
18,880 shares
Previously granted RSUs vested and converted on June 20, 2026
New RSU grant
14,180 units
RSUs granted on June 18, 2026, each for one common share
New stock option grant
21,270 options
Options granted on June 18, 2026 for Novavax common stock
Option exercise price
$9.13 per share
Exercise price for 21,270 stock options expiring June 18, 2036
Shares held after transactions
44,468 shares
Direct Novavax common stock holdings after June 20, 2026 activity
Key Terms
Restricted Stock Units, Stock Option (Right to Buy), Amended and Restated 2015 Stock Incentive Plan, vesting
4 terms
Restricted Stock Units financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with 21,270 shares underlying Novavax common stock."
Amended and Restated 2015 Stock Incentive Plan financial
"shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest"
vesting financial
"One hundred percent (100%) of the RSUs subject to this grant will vest on the first anniversary of the June 18, 2026 grant date"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What equity awards did Novavax (NVAX) director Margaret McGlynn receive?
Margaret McGlynn received 14,180 Restricted Stock Units and 21,270 stock options, each tied to one Novavax common share. The options have a $9.13 exercise price and both awards vest after one year of continued board service from the June 18, 2026 grant date.
What stock option terms were reported in this Novavax (NVAX) Form 4?
The filing shows a grant of 21,270 stock options with a $9.13 per-share exercise price. These options relate to Novavax common stock and will vest 100% on the first anniversary of the June 18, 2026 grant date, assuming continued board service, and expire on June 18, 2036.
What RSU activity did Novavax (NVAX) disclose for Margaret McGlynn?
Novavax reported two RSU events: a new grant of 14,180 RSUs on June 18, 2026, and the vesting and conversion of 18,880 previously granted RSUs into common shares on June 20, 2026. Each RSU converts into one share of Novavax common stock upon vesting.
What are the vesting conditions for the new Novavax (NVAX) RSU and option grants?
Both the 14,180 RSUs and 21,270 stock options vest 100% on the first anniversary of the June 18, 2026 grant date. Vesting is contingent on Ms. McGlynn’s continued service on Novavax’s Board of Directors through that one-year anniversary, under the company’s 2015 Stock Incentive Plan.